 | Up a level |
Journal Article
Joerger, M., Soo, R., Cho, B. C., Navarro Mendivil, A., Sayehli, C., Richly, H., Tai, D., Kim, D. -W., Wolf, J., Cassier, P., Ellinghaus, P., Hildebrandt, S., Behre, S., Helmbrecht, C., Kerpen, S., Zielinski, D., Ince, S., Rajagopalan, P., Ocker, M. and Schuler, M. (2016). Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Schuler, M., Cassier, P., Penel, N., Cathomas, R., Richly, H., Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Gruellich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P. and Joerger, M. (2018). Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway. Oncol. Res. Treat., 41. S. 321 - 322. BASEL: KARGER. ISSN 2296-5262
von Tresckow, B., Goebeler, M. E., Sayehli, C., Gundermann, S., Eichenauer, D., Aulitzky, W., Bacchus, L., Igel, S., Schwab, M., Sasse, S., Hauns, B., Mais, A., Hentsch, B., Kohlhof, H., Krauss, R., Krauss, B., Baumgartner, R., Vitt, D. and Engert, A. (2014). FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY). Haematologica, 99. S. 711 - 712. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078